Cyclerion Therapeutics announces a strategic collaboration with Medsteer to advance their lead program, CYC-126.
The collaboration aims to integrate Medsteer's technology into CYC-126, a potential first-in-class therapy for treatment-resistant depression.
CYC-126 is designed as a precision-delivered treatment using real-time patient feedback and EEG monitoring.
Strategic Collaboration with Medsteer
Cyclerion strengthens its development strategy by partnering with Medsteer for closed-loop anesthetic delivery systems.
Progress Towards Phase 2 POC Study
The company moves forward confidently towards initiating the Phase 2 proof-of-concept study for CYC-126 in 2026.
Individualized Treatment for TRD
CYC-126 aims to offer individualized and technology-enabled treatment for patients with treatment-resistant depression.
- The collaboration with Medsteer enhances Cyclerion's platform development and potentially reduces technical risks.
- CYC-126's innovative approach using real-time EEG monitoring could revolutionize the treatment paradigm for TRD and neuropsychiatric diseases.
Cyclerion Therapeutics is poised for significant advancements in the treatment of mental health disorders with the ongoing collaborations and progress on CYC-126.